Payment overview · 2025
General Payments
$150.16
7 reported records · 4 companies
Healthcare provider profile · identity verified
Terry Scott Baul, M.D.
Allopathic & Osteopathic Physicians|General Practice · DETROIT, MI · NPI 1942375837
Verified facts
What the public records show
CMS Open Payments records show Terry Scott Baul, M.D. received $150.16 in general payments during 2025 across 7 reported records.
Boston Scientific Corporation accounted for 30.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $45.04 | 30.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.07 | 27.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.06 | 24.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $26.99 | 18.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $150.16 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $45.04 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $41.07 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $26.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 318 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 229 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 179 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 165 | 37 |
| Simvastatin | Simvastatin | 158 | 44 |
| Famotidine | Famotidine | 144 | 23 |
| Lisinopril | Lisinopril | 143 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 108 | 20 |
| Furosemide | Furosemide | 101 | 25 |
| Metformin Hcl | Metformin Hcl | 98 | 24 |
| Omeprazole | Omeprazole | 96 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 20 |
| Ibuprofen | Ibuprofen | 89 | 20 |
| Baclofen | Baclofen | 87 | 19 |
| Losartan Potassium | Losartan Potassium | 87 | 25 |
| Potassium Chloride | Potassium Chloride | 87 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 25 |
| Buspirone Hcl | Buspirone Hcl | 77 | 15 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 76 | 14 |
| Celecoxib | Celecoxib | 74 | 14 |
| Montelukast Sodium | Montelukast Sodium | 66 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 12 |
| Eliquis | Apixaban | 62 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 59 | 13 |
| Linzess | Linaclotide | 58 | suppressed |
| Carvedilol | Carvedilol | 57 | 12 |
| Doxepin Hcl | Doxepin Hcl | 53 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 15 |
| Clonidine Hcl | Clonidine Hcl | 49 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 49 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 48 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 48 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 48 | suppressed |
| Ezetimibe | Ezetimibe | 47 | suppressed |
| Hydrocortisone | Hydrocortisone | 47 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 44 | suppressed |
| Nifedipine Er | Nifedipine | 42 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 41 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 40 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 36 | suppressed |
| Allopurinol | Allopurinol | 35 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Lidocaine | Lidocaine | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Lansoprazole | Lansoprazole | 34 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 27 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Klor-Con | Potassium Chloride | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Desloratadine | Desloratadine | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Indomethacin | Indomethacin | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 12 |
| Glipizide | Glipizide | 14 | suppressed |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $150.16 · 7 records | Boston Scientific Corporation | Cologuard Collection Kit, FARXIGA, Kerendia, WATCHMAN FLX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error